NTRK1, 2,3 And Other Rare Mutations In NSCLC
Update: 2024-08-30
Description
In this TOGA podcast, we provide an overview of the treatment options for rare subtypes of oncogene driven NSCLC that are now readily identified in the MBS-reimbursed small gene panel including NTRK1, 2,3 and other rare mutations in NSCLC. The importance of testing all patients is discussed as well as what to do when resistance occurs.
Associate Professor Steven Kao, Medical Oncologist from Chris O’Brien Lifehouse and Clinical Associate Professor Sydney Medical School, Faculty of Medicine and Health is joined by Professor Wendy Cooper, senior staff specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, Anatomical Clinical Stream Lead for NSW Health Pathology, a Clinical Professor at the University of Sydney and a Conjoint Professor at the University of Western Sydney and also Professor Ben Solomon head of the lung Medical Oncology Service and a Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division at Peter MacCallum Cancer Centre as well as a Founding Board member of TOGA.
Associate Professor Steven Kao, Medical Oncologist from Chris O’Brien Lifehouse and Clinical Associate Professor Sydney Medical School, Faculty of Medicine and Health is joined by Professor Wendy Cooper, senior staff specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, Anatomical Clinical Stream Lead for NSW Health Pathology, a Clinical Professor at the University of Sydney and a Conjoint Professor at the University of Western Sydney and also Professor Ben Solomon head of the lung Medical Oncology Service and a Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division at Peter MacCallum Cancer Centre as well as a Founding Board member of TOGA.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
